亚洲综合大片69999,日韩一区二区三区aaa,亚洲av熟女国产一区二区三区视,国产亚洲一区二区三区精品久久

加入收藏 | 設為首頁 | 聯(lián)系我們

產(chǎn)品搜索

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73192SLC34A2-ROS1 G2032R/BaF3

SLC34A2-ROS1 G2032R/BaF3
名稱 SLC34A2-ROS1 G2032R/BaF3
型號 CBP73192
報價
特點 SLC34A2-ROS1 [G2032R]/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細內容
CBP73192
I. Introduction

Cell Line Name：

SLC34A2-ROS1 [G2032R]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).


III. Representative Data

1. WB of SLC34A2-ROS1 [G2032R]/BaF3expression

CBP73192 WB.png


Figure 1. Protein Expression of ROS1 detected by antibody


2.Sanger Sequencing of SLC34A2-ROS1 Fusion and G2032R mutation

CBP73192 sanger-1.png

Figure 2. SLC34A2-ROS1 Fusion

CBP73192 sanger2.png

Figure 3. ROS1 p.G2032R


3. Anti-proliferation assay

CBP73192 fig.png

Figure 4. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1 [G2032R]/BaF3 Stable Cell Line.



如果你對CBP73192SLC34A2-ROS1 G2032R/BaF3感興趣，想了解更詳細的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細地址：

  • 補充說明：

  • 驗證碼：

    請輸入計算結果（填寫阿拉伯數(shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
欧美高清一二三区| avtt天堂网先锋伦理| 国产163黄网人看人人爽| 欧美久久精品免费看C片| 99热这里有精品在线观看| 老司机免费福利午夜入口| 国产午夜福利片无码视频| 日本熟妇一区二区三区四区| 亚洲高清中文字幕一区二区三区| 男人操女人下面国产剧情| 国产精品毛片一区视频播| 人妻人久久精品中文字幕| 欧美一区二区三区高清性群p| 欧美日韩欧美国产中文字幕| 亚洲高清中文字幕一区二区三区| 日韩一区二区三区夜色视频| 猛哥操女人B视频| 伊人网在线免费视频| 操国产骚逼逼逼逼逼逼逼| 巨屌抽插舔阴视频| 插女人下面高潮视频| 日本男人捅女人机机| 日本一二区视频在线观看| 骚女性爱视频在线看| 男人透女人视频短篇| 中文字幕乱码一区三区免费| 色噜噜人妻丝袜中文字幕| 三级无码日B视频| 在线无码一区二区三区不卡| 日本潘金莲三级bd高清| 99视频在线看免费视频| 91kaobi视频在线| 国产区高清在线一区二区三区| 骚穴 操我 视频| 亚洲国产AV精品一区二区色欲| 男人草女人的骚逼逼| 欧美 日韩 亚洲 熟女| 99热这里只有精品98| 视频一区视频二区制服丝袜| 插到底啊啊啊视频| 国产欧美一二区不卡视频|